The strain No. 43708 was isolated from a soil sample obtained from Akashi City, Hyogo Prefecture.
The methods described by SHIRLING and GOTTLIEB') were principally employed for the taxonomic studies. Morphological observations were made with light and electron microscopes on cultures grown at 30°C for 14 days on yeast -malt extract agar, oatmeal agar or inorganic salts -starch agar. The mature spores occurred in chains of more than 30 spores forming Rectiflexibiles (Fig. 1) . The spores were cylindrical and 0.5-0.7 x 1.3-1.5 um in size. Spore surfaces were smooth or warty (Fig. 2) .
Cultural characteristics were observed on ten kinds of media described by SHIRLING and GOTTLIEB4) and WAKSMAN.5) Incubations were made at 30°C for 14 days. The color names used in this study were based on the Color Standard (Nihon Shikisai Co., Ltd.). Colonies were in the gray color series when grown on oatmeal agar, yeast -malt extract agar or inorganic salts -starch agar. Soluble pigment was produced in yeast -malt extract agar and other agars. Results are shown in Table 1 . The cell wall analysis was performed by the methods of BECKER et a1.6) and YAMAGUCHL7) Analysis of whole cell hydrolysates of strain No. 43708 showed that it contained LL-diaminopimelic acid and glycine. Accordingly, the cell wall of the strain was of type I. Table 4 . The fermentation was carried out at 30°C for 4 days, with aeration of 160 acetonitrile. Biphenomycins A and B were eluted from 60 ml to 80 ml (fraction I), and from 85 ml to 120 ml (fraction II) respectively.
Fraction I was desalted with CM-Sephadex C-25 (H+ form, 1 liter, Pharmacia Fine Chemicals).
The active fraction (400 ml) was dried in vacuo to give a pale brown powder (30 mg). The powder was suspended in 1 N HCl (10 ml). Then, a solution of 28 % aqueous ammonium hydroxide was added with stirring at 50°C to adjust to pH 2. The solution was kept overnight at 5°C to produce colorless needles of biphenomycin A (20 mg). Fraction II was desalted with CM-Sephadex C-25 (H+ form, 1 liter) and then concentrated in vacuo to 2 ml. Further purification was achieved by a high performance liquid chromatography on pBondapak C18 (7.8 mm x 300 mm, Waters Associates Ltd.) using 0.1 M K2HPO4 -H3PO4 buffer (pH 4.8) containing 10 % acetonitrile, with pressure of 141 kg/cm2, flow rate at 2 ml/minute. Under these conditions, retention time of biphenomycins A and B were 4.2 minutes and 4.8 minutes, respectively. The active fraction containing biphenomycin B was also desalted with CM-Sephadex C-25
(H+ form). According to the same procedure for crystallization as biphenomycin A, colorless needles of biphenomycin B (2 mg) were obtained.
Physico-chemical Properties
The physico-chemical properties of biphenomycins A and B are summarized in Table 5 . Their OF ANTIBIOTICS NOV. 1985 A single intravenous administration of 500 mg/kg of biphenomycin A into ICR mice did not result in any toxic symptoms for 1 week after injection.
The in vivo activity of biphenomycin A against experimental infections due to bacteria was examined. Mice were challenged intraperitoneally with clinical isolates of S. aureus and other organisms.
The in vivo activity of biphenomycin A against these infections is expressed in terms of the ED50 values.
The results are shown in Table 8 . Biphenomycin A has protective efficacy against infections by various strains of Gram-positive bacteria. It is to be noticed that the antibiotic is active in vitro and in vivo against S. aureus 2508 and 2485 which are highly resistant to ampicillin. We have described in this paper that biphenomycins A and B are amphoteric, water-soluble, peptide antibiotics. Furthermore, the biphenomycins are novel cyclic peptides containing a biphenyl moiety included in a 15-membered ring as described in succeeding papers. Biphenomycins A and B showed intense antibacterial activity in the serum medium containing 20% horse serum, but poor activity was observed in complex media such as Mueller-Hinton medium and bouillon medium (Table 6 ). Remarkably the antibacterial activity was inhibited when peptone was added to the serum medium (unpublished data). This suggests that the activity of biphenomycins A and B may be competitively inhibited by peptides in assay medium.
Biphenomycin A is effective against bacterial infections in mice, and such efficacy in vivo exceeds our expectation presumed from the activity in vitro. Although the reason for the superior efficacy in vivo is not yet known, it may be due to the fact that the antibiotic shows intense antibacterial activity in the serum medium.
Our experiments in this paper show the possibility that these compounds may be clinically useful antibiotics of a new type.
